Presurgery Adhesion Molecules and Angiogenesis Biomarkers Are Differently Associated with Outcomes in Colon and Rectal Cancer: Results from the ColoCare Study
Published in
Cancer Epidemiology, Biomarkers & Prevention, June 2022
Cell-to-cell adhesion and angiogenesis are hallmarks of cancer. No studies have examined associations of adhesion-molecules and angiogenesis biomarkers with clinical outcomes in colorectal cancer (CRC).
In pre-surgery serum from n=426 CRC patients (stage I-III) we investigated associations of CRP, SAA, adhesion molecules (sICAM-1, sVCAM-1), and angiogenesis markers (VEGF-A, and -D) with overall survival (OS), disease-free survival (DFS), and risk of recurrence. We computed hazard ratios (HR) and 95% confidence intervals; adjusted for age, sex, BMI, stage, site, and study site, stratified by tumor site in exploratory analyses.
N=65 (15%) were deceased, 59 patients (14%) had a recurrence after a median follow-up of 31 months. We observed significant associations of biomarkers with OS, DFS, and risk of recurrence on a continuous scale and comparing top to bottom tertile, with HRs ranging between 1.19 - 13.92. CRP was associated with risk of death and recurrence in patients in the top tertile compared to patients in the bottom tertile, e.g., risk of recurrence HRQ3-Q1:13.92 (1.72, 112.56). Significant heterogeneity between biomarkers and clinical outcomes was observed in stratified analysis by tumor site for CRP, SAA, sICAM-1, sVCAM-1, and VEGF-D. VEGF-D was associated with a 3-fold increase in risk of death for rectal cancer (HRlog2: 3.26; 95% CI: 1.58-6.70) compared to no association for colon cancer (HRlog2: 0.78; 95% CI: 0.35-1.73; pheterogenity =0.01).
Adhesion molecules and angiogenesis biomarkers are independent prognostic markers for CRC, with differences by tumor site.
There is need for tailored treatment for colon and rectal cancer.
This research output has an Altmetric Attention Score of 70. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 November 2022.
All research outputs
#740,784
of 32,444,503 outputs
Outputs from Cancer Epidemiology, Biomarkers & Prevention
#257
of 5,814 outputs
Outputs of similar age
#15,067
of 462,578 outputs
Outputs of similar age from Cancer Epidemiology, Biomarkers & Prevention
#4
of 79 outputs
Altmetric has tracked 32,444,503 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,814 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 16.2. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 462,578 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 79 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.
